What should I know about Bristol Myers Squibb?
Bristol Myers Squibb (BMS) is a US pharmaceutical company that develops medicines for cancer, heart disease, immune conditions and neurological disorders. It was created in 1989 when Bristol-Myers (founded 1887) merged with Squibb (founded in Brooklyn in 1858), and it bought Celgene for $74 billion in 2019. It is registered in Princeton, New Jersey, and has its corporate headquarters in Lawrenceville, New Jersey. Chris Boerner is chairman and chief executive. In the second quarter of 2026 it reported revenue of about $13 billion, up 5%.
What are Bristol Myers Squibb's main drugs?
BMS's biggest drug is Eliquis, a blood thinner developed with Pfizer, which earned about $4.5 billion in the second quarter of 2026, up 21%. Opdivo, a cancer immunotherapy, fell 4% to $2.5 billion as patients moved to its subcutaneous version Qvantig, which made $261 million. Other products include Camzyos for heart disease ($416 million, up 59%), Breyanzi and Reblozyl. The schizophrenia drug Cobenfy rose 81% to $63 million. BMS's "growth portfolio" of newer products made $7.6 billion, nearly 60% of revenue. Eliquis was about 30% of 2025 revenue.
What is Bristol Myers Squibb currently developing?
BMS is trying to replace revenue from older drugs with newer ones. It raised its 2026 forecast, expecting Eliquis to grow 20–25%, while its older products decline 4–6%. However, the milvexian atrial fibrillation readout has slipped to the first quarter of 2027 because events accrued more slowly than expected, and readouts of Cobenfy's Alzheimer's trials are delayed to early 2027. BMS is also working with BioNTech on pumitamig, a lung cancer treatment that has several pivotal trials under way.
Have there been any controversies involving Bristol Myers Squibb?
In May 2024 a Hawaii court ordered Bristol Myers Squibb and three Sanofi subsidiaries to pay a combined $916 million in a case over their marketing of the blood thinner Plavix. The state alleged they failed to disclose that about 30% of patients, particularly non-Caucasians, might respond less well to the drug, and the judge found they had acted in bad faith. Hawaii sued in 2014 and was the last of five states to do so. The companies said the penalty was out of proportion and that they would appeal.
Is Bristol Myers Squibb publicly traded, and how big is it?
Yes. BMS trades on the New York Stock Exchange under the ticker BMY and is part of the S&P 500. Its market value was about $122 billion on 6 October 2026, with the shares at about $59.59 and a dividend yield above 4%. In the second quarter of 2026 it reported revenue of about $13 billion and held $11.5 billion in cash. It employs about 32,500 people.